SecBot SecBot
PRESS-RELEASE ·Filed Apr 8, 2026

ANIP

ANI Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor near-term sales uptake and gross margin trends, as limited-competition generics typically offer strong profitability. This approval adds to ANI’s track record of successful ANDA approvals and may support valuation re-rating if commercial execution continues.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$79.01
T+0 close · Apr 8, 2026 · via day close
Latest settled
+8.88%
T+60 · $86.03
Vs SPY
−1.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $79.01entry
  2. T+1 · 8mo ago +1.43%α +0.86% · $80.14
  3. T+5 · 7mo ago −3.20%α −6.72% · $76.48
  4. T+20 · 7mo ago +7.11%α −1.43% · $84.63
  5. T+60 · 5mo ago +8.88%α −1.57% · $86.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, the generic version of Monoket®, reinforcing its generics pipeline and R&D execution. The product targets a limited-competition market, supporting near-term revenue diversification.

Key Facts

  • FDA approved ANI's Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg.
  • Product launched immediately as a generic version of Monoket®.
  • Indication is for cardiovascular conditions, with limited competition expected.
  • Strengthens ANI’s Generics business and R&D track record.

Financial Impact

Moderate revenue contribution expected; exact sales figures not disclosed but positioned as part of steady product launch cadence.

revenueproduct pipelinemarket share

Risk Factors

  • Uncertainty around market adoption and competition despite 'limited-competition' claim.
  • Supply chain or manufacturing delays could hinder revenue realization.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3269952

Track record

34 reports on ANIP

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +7.08% at T+60 after the Jul 16, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026